Effectiveness and tolerance of anti‐inflammatory drugs' add‐on therapy in major mental disorders: a systematic qualitative review

@article{Fond2014EffectivenessAT,
  title={Effectiveness and tolerance of anti‐inflammatory drugs' add‐on therapy in major mental disorders: a systematic qualitative review},
  author={Guillaume Fond and Nora Hamdani and Fl{\'a}vio Kapczinski and Wahid Boukouaci and No{\'e}mie Drancourt and Aroldo A Darg{\'e}l and J Oliveira and Emmanuel Le Guen and Emeline Marlinge and Ryad Tamouza and Marion Leboyer},
  journal={Acta Psychiatrica Scandinavica},
  year={2014},
  volume={129}
}
To provide a systematic review of the literature regarding the efficacy of anti‐inflammatory drugs in three major mental disorders [major depressive disorder (MDD), schizophrenia and bipolar disorders]. 
Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta‐analysis of randomized controlled trials
This study aimed to perform a comprehensive meta‐analysis of minocycline augmentation therapy in patients with schizophrenia receiving antipsychotic agents.
Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis
TLDR
Further high quality trials are needed before making recommendations for the routine clinical use of anti-inflammatories in the treatment of mood disorders, as well as showing a statistically significant improvement in the secondary outcome measure. Expand
Recovery from major depressive disorder episode after non‐pharmacological treatment is associated with normalized cytokine levels
TLDR
This follow-up study investigated whether CRP and elevated plasma cytokine levels observed before treatment of an acute episode of MDD are normalized during non‐pharmacological treatment. Expand
Cyclooxygenase Inhibition Safety and Efficacy in Inflammation-Based Psychiatric Disorders
TLDR
A critical analysis of the use of COX inhibitors in the last ten years of clinical trials of the major psychiatric disorders was carried out and found that adjunctive administration of COx inhibitors to classic clinical treatments seems to improve the prognosis of people who suffer from psychiatric disorders. Expand
A pilot, open‐label, 8‐week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression
TLDR
If adjunctive minocycline mitigates depressive symptom severity and improves cognitive function in individuals with bipolar I/II disorder (BD). Expand
Inflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes
TLDR
The objective was to investigate treatment effectiveness and safety aspects of concomitant SSRI use with NSAIDs or paracetamol and to establish a protocol for simultaneous evaluation of potential adverse events. Expand
Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: A systematic review and meta-analysis
TLDR
The current review and meta-analysis indicates moderate immunomodulating effects of SSRI treatment for MDD, which suggests SSRIs may owe some of their therapeutic effect to their anti-inflammatory properties. Expand
Inflammation in psychiatric disorders
  • G. Fond
  • Medicine
  • European Psychiatry
  • 2014
TLDR
A systematic review of the literature regarding the efficacy of anti-inflammatory drugs in MDD, schizophrenia and bipolar disorders found that polyunsaturated fatty acids (PUFAs) have anti- inflammatory properties and are effective in major depression with a good tolerance profile. Expand
A critical review of the efficacy of non-steroidal anti-inflammatory drugs in depression
TLDR
The efficacy of NSAIDs on depressive symptoms appears negligible, however firm conclusions are difficult given the inconsistent findings and substantial methodological heterogeneity. Expand
Are Non-steroidal Anti-Inflammatory Drugs Clinically Suitable for the Treatment of Symptoms in Depression-Associated Inflammation?
  • B. Baune
  • Medicine
  • Current topics in behavioral neurosciences
  • 2017
TLDR
Although meta-analyses appear to support the use of NSAIDs in acute depression, the overall effect is mainly biased by the effects of celecoxib for which the best evidence exists to date, and the possible impact of anti-inflammatory treatments on immune changes in different phases of depression warrants caution. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 202 REFERENCES
The impact of major depressive disorder on the short‐ and long‐term outcome of Crohn's disease treatment with infliximab
TLDR
This data indicates that a central nervous system disorder related to major depressive disorder may be a potential mediating role in the course of Crohn's disease. Expand
Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double‐blind, randomized, placebo‐controlled study
TLDR
To investigate whether the cox‐2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases, a new drug is developed that combines the former and the latter into a single pill. Expand
A psychoneuroimmunological review on cytokines involved in antidepressant treatment response
TLDR
The literature exploring the role that cytokine functioning plays in the pathogenesis and treatment of depressive illness is reviewed, and on how treatment response might be affected by genetic variants of cytokines. Expand
Antidepressant drugs and experimental inflammation.
TLDR
There are strong indications that the anti-inflammatory action of antidepressant drugs is involved in their well documented analgesic effect, and experimental data reported here contribute to explain the reduction of pain observed after the acute administration of antidepressants in clinical conditions. Expand
Association between anti‐TNF‐α therapy and all‐cause mortality
To compare mortality among patients with selected autoimmune diseases treated with anti‐tumor necrosis factor alpha (TNF‐α) agents with similar patients treated with non‐biologic therapies.
Infliximab improves health‐related quality of life in the presence of comorbidities among patients with moderate‐to‐severe psoriasis
TLDR
This study highlights the need to understand more fully the role that emotions play in the development of psoriasis and how these emotions can be affected by treatment. Expand
COX-2 Inhibitors as Adjunctive Therapy in Schizophrenia
TLDR
The COX-2 inhibitor celecoxib has been tested as a possible adjunctive therapeutic approach in the treatment of schizophrenia, and it is demonstrated that this effect may be limited to patients with recent-onset schizophrenia. Expand
Self‐reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens
TLDR
Etanercept, a fully human tumour necrosis factor‐α receptor fusion protein, is approved for treatment of both psoriasis and psoriatic arthritis. Expand
The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?
TLDR
Supporting evidence is reviewed for the hypothesis that disturbances in inflammatory homeostasis, as marked by elevated TNF-alpha levels, are salient to the pathophysiology of BD and provide a platform for novel drug discovery. Expand
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.
TLDR
Aspirin given as adjuvant therapy to regular antipsychotic treatment reduces the symptoms of schizophrenia spectrum disorders, and is more pronounced in those with the more altered immune function. Expand
...
1
2
3
4
5
...